Evidence map›Paper›PMID 39253480›Full record

ArticlebioRxiv : the preprint server for biology2024

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

Francisca Nunes de Almeida, Alessandro Vasciaveo, Ainsley Mike Antao, Min Zou, Matteo Di Bernardo, Simone de Brot, Antonio Rodriguez-Calero, Alexander Chui, Alexander L E Wang, Nicolas Floc'h and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Francisca Nunes de Almeida
Alessandro Vasciaveo
Ainsley Mike Antao
Min Zou
Matteo Di Bernardo
Simone de Brot
Antonio Rodriguez-Calero
Alexander Chui
Alexander L E Wang
Nicolas Floc'h
Jaime Y Kim
Stephanie N Afari
Timur Mukhammadov
Juan Martín Arriaga
Jinqiu Lu
Michael M Shen
Mark A RubinORCID 0000-0002-8321-9950
Andrea Califano
Cory Abate-Shen

Funding

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5M
Studying the evolution of drug resistance in prostate cancer at the single cell levelU54CA274506 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2023 to 2026
$9.1M
NCI NIH HHS R35 CA197745NCI NIH HHS U54 CA274506
6 · The paper itself

Abstract

Although localized prostate cancer is relatively indolent, advanced prostate cancer manifests with aggressive and often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify drivers of aggressive prostate cancer, we leveraged Summary: Using an unbiased forward mutagenesis screen in an autochthonous mouse model, we have investigated mechanistic determinants of aggressive prostate cancer. SIRT1 emerged as a key regulator of neuroendocrine prostate cancer differentiation and a potential target for therapeutic intervention.

Identifiers

PMID39253480
PMCPMC11383054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.